Clearside Biomedical, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 4.83 million compared to USD 9.66 million a year ago. Basic loss per share from continuing operations was USD 0.08 compared to USD 0.16 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.34 USD | +6.35% | +2.29% | +14.53% |
Apr. 16 | Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors | CI |
Mar. 18 | Clearside Biomedical Names Victor Chong Chief Medical Officer | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.53% | 100M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- CLSD Stock
- News Clearside Biomedical, Inc.
- Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023